Details of the Drug

General Information of Drug (ID: DM3NF5G)

Drug Name
Delavirdine
Synonyms
DLV; Rescriptor; SPP; DELAVIRDINE MESYLATE; Delavirdine [INN]; U 90152; BHAP-U 90152; Delavirdine (INN); Rescriptor (TM);Rescriptor (TN); U-90152; U-90152S; PNU-90152-T; Delavirdine (*Mesylate salt*); U90152S (*Mesylate salt*); Delavirdine(U-90152) & .a.IFN; N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide; N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide; N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide; N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide; N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-& alpha-Interferon; (1-(5-METHANSULPHONAMIDO-1H-INDOL-2-YL-CARBONYL)4-[METHYLAMINO)PYRIDINYL]PIPERAZINE; (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide); 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; 1-(5-Methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl]piperaz; 2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Therapeutic Class
Anti-HIV Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 456.6
Topological Polar Surface Area (xlogp) 2.4
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption
The drug is rapidly absorbed [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
85% of drug becomes completely available to its intended biological destination(s) [4]
Elimination
2.5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 5.8 hours [5]
Metabolism
The drug is metabolized via the hepatic [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 14.6089 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.00081 mg/mL [3]
Chemical Identifiers
Formula
C22H28N6O3S
IUPAC Name
N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
Canonical SMILES
CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C
InChI
InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3
InChIKey
WHBIGIKBNXZKFE-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5625
ChEBI ID
CHEBI:119573
CAS Number
136817-59-9
DrugBank ID
DB00705
TTD ID
D0G6SD
VARIDT ID
DR00619
INTEDE ID
DR0434
ACDINA ID
D00176

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [12]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Delavirdine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
MK-1439 DM215WE Minor Decreased metabolism of Delavirdine caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Delavirdine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Fostemsavir DM50ILT Moderate Decreased metabolism of Delavirdine caused by Fostemsavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Dolutegravir DMCZGRE Minor Decreased metabolism of Delavirdine caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Saquinavir DMG814N Moderate Decreased metabolism of Delavirdine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Atazanavir DMSYRBX Moderate Decreased metabolism of Delavirdine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [69]
Maraviroc DMTL94F Major Decreased metabolism of Delavirdine caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Delavirdine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Altered absorption of Delavirdine caused by Sodium bicarbonate. Acidosis [5C73] [71]
Clindamycin DM15HL8 Moderate Decreased metabolism of Delavirdine caused by Clindamycin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [72]
Tretinoin DM49DUI Moderate Decreased metabolism of Delavirdine caused by Tretinoin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [73]
Repaglinide DM5SXUV Moderate Decreased metabolism of Delavirdine caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [74]
Pioglitazone DMKJ485 Moderate Decreased metabolism of Delavirdine caused by Pioglitazone mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [75]
Nateglinide DMLK2QH Moderate Decreased metabolism of Delavirdine caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [76]
Ivosidenib DM8S6T7 Major Decreased metabolism of Delavirdine caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [77]
Midostaurin DMI6E0R Major Decreased metabolism of Delavirdine caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [78]
Idarubicin DMM0XGL Moderate Decreased clearance of Delavirdine due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [79]
Arn-509 DMT81LZ Major Increased metabolism of Delavirdine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [80]
Gilteritinib DMWQ4MZ Major Decreased metabolism of Delavirdine caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [81]
Oliceridine DM6MDCF Major Decreased metabolism of Delavirdine caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [82]
Donepezil DMIYG7Z Minor Decreased metabolism of Delavirdine caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [83]
Ivabradine DM0L594 Major Decreased metabolism of Delavirdine caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [84]
Bepridil DM0RKS4 Moderate Decreased metabolism of Delavirdine caused by Bepridil mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [85]
Dronedarone DMA8FS5 Major Decreased metabolism of Delavirdine caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [84]
Nifedipine DMSVOZT Moderate Decreased metabolism of Delavirdine caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [71]
Bedaquiline DM3906J Moderate Decreased metabolism of Delavirdine caused by Bedaquiline mediated inhibition of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [86]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Delavirdine caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [87]
Cilostazol DMZMSCT Major Decreased metabolism of Delavirdine caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [88]
Budesonide DMJIBAW Major Decreased metabolism of Delavirdine caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [89]
Lisdexamfetamine DM6W8V5 Moderate Decreased metabolism of Delavirdine caused by Lisdexamfetamine mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [71]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Delavirdine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [90]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Delavirdine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [71]
Rabeprazole DMMZXIW Moderate Decreased absorption of Delavirdine due to altered gastric pH caused by Rabeprazole. Bacterial infection [1A00-1C4Z] [71]
Troleandomycin DMUZNIG Minor Decreased metabolism of Delavirdine caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [91]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Delavirdine caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [92]
Cariprazine DMJYDVK Major Decreased metabolism of Delavirdine caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [93]
Erdafitinib DMI782S Major Decreased metabolism of Delavirdine caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [94]
Pexidartinib DMS2J0Z Major Decreased metabolism of Delavirdine caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [95]
Loperamide DMOJZQ9 Major Decreased metabolism of Delavirdine caused by Loperamide mediated inhibition of CYP450 enzyme. Bowel habit change [ME05] [96]
Talazoparib DM1KS78 Moderate Decreased clearance of Delavirdine due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [97]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Delavirdine caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [98]
Lapatinib DM3BH1Y Major Decreased metabolism of Delavirdine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
HKI-272 DM6QOVN Major Decreased metabolism of Delavirdine caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [99]
LY2835219 DM93VBZ Major Decreased metabolism of Delavirdine caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [100]
Esterified estrogens DM9KZDO Minor Decreased metabolism of Delavirdine caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [101]
Tucatinib DMBESUA Moderate Decreased metabolism of Delavirdine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [102]
Palbociclib DMD7L94 Major Decreased metabolism of Delavirdine caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [103]
Letrozole DMH07Y3 Minor Decreased metabolism of Delavirdine caused by Letrozole mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [101]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Delavirdine caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Bosutinib DMTI8YE Major Decreased metabolism of Delavirdine caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Trastuzumab Emtansine DMU1LXS Moderate Decreased metabolism of Delavirdine caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Estradiol DMUNTE3 Minor Decreased metabolism of Delavirdine caused by Estradiol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [101]
Atorvastatin DMF28YC Moderate Decreased metabolism of Delavirdine caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [104]
Macitentan DMP79A1 Major Decreased metabolism of Delavirdine caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [105]
PF-04449913 DMSB068 Major Decreased metabolism of Delavirdine caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [106]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Delavirdine caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [107]
Salmeterol DMIEU69 Major Decreased metabolism of Delavirdine caused by Salmeterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [84]
Indacaterol DMQJHR7 Minor Decreased metabolism of Delavirdine caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [108]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Delavirdine caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [87]
Dihydrocodeine DMB0FWL Minor Decreased metabolism of Delavirdine caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [91]
Levomilnacipran DMV26S8 Major Decreased metabolism of Delavirdine caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [109]
Anisindione DM2C48U Moderate Decreased metabolism of Delavirdine caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [110]
Regorafenib DMHSY1I Moderate Decreased metabolism of Delavirdine caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [84]
Irinotecan DMP6SC2 Major Decreased metabolism of Delavirdine caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [111]
Drospirenone DM1A9W3 Major Decreased metabolism of Delavirdine caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [84]
Levonorgestrel DM1DP7T Minor Decreased metabolism of Delavirdine caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [91]
Ulipristal DMBNI20 Minor Decreased metabolism of Delavirdine caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [88]
Mestranol DMG3F94 Minor Decreased metabolism of Delavirdine caused by Mestranol mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [91]
Levobupivacaine DM783CH Moderate Decreased metabolism of Delavirdine caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [88]
Alfentanil DMVO0UB Major Decreased metabolism of Delavirdine caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [112]
Mifepristone DMGZQEF Major Decreased metabolism of Delavirdine caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [113]
Osilodrostat DMIJC9X Major Decreased metabolism of Delavirdine caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [114]
Ivacaftor DMZC1HS Major Decreased metabolism of Delavirdine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [84]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Delavirdine caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [84]
Vilazodone DM4LECQ Major Decreased metabolism of Delavirdine caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [115]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Delavirdine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [116]
Escitalopram DMFK9HG Moderate Decreased metabolism of Delavirdine caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [117]
OPC-34712 DMHG57U Major Decreased metabolism of Delavirdine caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [118]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Delavirdine caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [119]
[3H]estrone-3-sulphate DMGPF0N Minor Decreased metabolism of Delavirdine caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [91]
Oxybutynine DMJPBAX Minor Decreased metabolism of Delavirdine caused by Oxybutynine mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [101]
Ospemifene DMC4GEI Moderate Decreased metabolism of Delavirdine caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [120]
Ingrezza DMVPLNC Major Additive CNS depression effects by the combination of Delavirdine and Ingrezza. Dystonic disorder [8A02] [121]
Diazepam DM08E9O Minor Decreased metabolism of Delavirdine caused by Diazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [101]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Delavirdine caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [122]
Primidone DM0WX6I Major Increased metabolism of Delavirdine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [80]
Felbamate DM1V5ZS Moderate Increased metabolism of Delavirdine caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [87]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Delavirdine caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [87]
Cenobamate DMGOVHA Moderate Increased metabolism of Delavirdine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [87]
Tiagabine DMKSQG0 Minor Decreased metabolism of Delavirdine caused by Tiagabine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [101]
Stiripentol DMMSDOY Moderate Decreased metabolism of Delavirdine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [88]
Fosphenytoin DMOX3LB Major Increased metabolism of Delavirdine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [123]
Brivaracetam DMSEPK8 Minor Decreased metabolism of Delavirdine caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [88]
Lacosamide DMVM6QR Moderate Decreased metabolism of Delavirdine caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [84]
Phenobarbital DMXZOCG Major Increased metabolism of Delavirdine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [80]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Delavirdine caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [87]
Cannabidiol DM0659E Minor Decreased metabolism of Delavirdine caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [88]
Bay 80-6946 DMLOS5R Major Decreased metabolism of Delavirdine caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [124]
Tazemetostat DMWP1BH Major Decreased metabolism of Delavirdine caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [125]
Solifenacin DMG592Q Major Decreased metabolism of Delavirdine caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [84]
Mirabegron DMS1GYT Minor Decreased metabolism of Delavirdine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [126]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Delavirdine caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [127]
Itraconazole DMCR1MV Moderate Decreased metabolism of Delavirdine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [128]
Terbinafine DMI6HUW Moderate Decreased metabolism of Delavirdine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [129]
Dexlansoprazole DM1DBV5 Moderate Decreased absorption of Delavirdine due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [71]
Ripretinib DM958QB Major Decreased metabolism of Delavirdine caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [84]
Sunitinib DMCBJSR Moderate Decreased metabolism of Delavirdine caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [84]
Avapritinib DMK2GZX Major Decreased metabolism of Delavirdine caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [88]
Colchicine DM2POTE Major Decreased metabolism of Delavirdine caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [130]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Delavirdine caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [87]
Simeprevir DMLUA9D Major Decreased metabolism of Delavirdine caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [84]
Daclatasvir DMSFK9V Major Decreased metabolism of Delavirdine caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [88]
Rifapentine DMCHV4I Moderate Increased metabolism of Delavirdine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [87]
Brentuximab vedotin DMWLC57 Moderate Decreased metabolism of Delavirdine caused by Brentuximab vedotin mediated inhibition of CYP450 enzyme. Hodgkin lymphoma [2B30] [88]
Fluvastatin DM4MDJY Moderate Decreased metabolism of Delavirdine caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [131]
BMS-201038 DMQTAGO Major Decreased metabolism of Delavirdine caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [84]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Delavirdine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [132]
Aliskiren DM1BV7W Moderate Decreased metabolism of Delavirdine caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [111]
Levamlodipine DM92S6N Moderate Decreased metabolism of Delavirdine caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [71]
Felodipine DMOSW35 Moderate Decreased metabolism of Delavirdine caused by Felodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [71]
Quinapril DMR8H31 Moderate Decreased absorption of Delavirdine due to formation of complexes caused by Quinapril. Hypertension [BA00-BA04] [88]
Conivaptan DM1V329 Major Decreased metabolism of Delavirdine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [84]
Tolvaptan DMIWFRL Major Decreased metabolism of Delavirdine caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [84]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Delavirdine caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [88]
Retapamulin DM9JXB7 Minor Decreased metabolism of Delavirdine caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [133]
TP-434 DM5A31S Minor Decreased metabolism of Delavirdine caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [134]
Berotralstat DMWA2DZ Major Decreased clearance of Delavirdine due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [85]
Suvorexant DM0E6S3 Major Decreased metabolism of Delavirdine caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [84]
Amobarbital DM0GQ8N Moderate Increased metabolism of Delavirdine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [87]
Ramelteon DM7IW9J Moderate Decreased metabolism of Delavirdine caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [135]
Triazolam DMETYK5 Major Decreased metabolism of Delavirdine caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [71]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Delavirdine caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [136]
ITI-007 DMUQ1DO Major Decreased metabolism of Delavirdine caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [137]
Alosetron DML2A03 Moderate Decreased metabolism of Delavirdine caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [138]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Delavirdine caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [139]
Naloxegol DML0B41 Major Decreased metabolism of Delavirdine caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [84]
Pemigatinib DM819JF Major Decreased metabolism of Delavirdine caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [140]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Delavirdine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [88]
Brigatinib DM7W94S Major Decreased metabolism of Delavirdine caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [141]
Ceritinib DMB920Z Major Decreased metabolism of Delavirdine caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [84]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Delavirdine caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [142]
Osimertinib DMRJLAT Major Decreased metabolism of Delavirdine caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [143]
Pralsetinib DMWU0I2 Major Decreased metabolism of Delavirdine caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [144]
Capmatinib DMYCXKL Major Decreased metabolism of Delavirdine caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [145]
Selpercatinib DMZR15V Major Decreased metabolism of Delavirdine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [146]
Artemether DM48QOT Major Decreased metabolism of Delavirdine caused by Artemether mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [84]
Halofantrine DMOMK1V Major Decreased metabolism of Delavirdine caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [147]
Idelalisib DM602WT Moderate Decreased metabolism of Delavirdine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [148]
GDC-0199 DMH0QKA Major Decreased metabolism of Delavirdine caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [149]
IPI-145 DMWA24P Major Decreased metabolism of Delavirdine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [150]
Acalabrutinib DM7GCVW Major Decreased metabolism of Delavirdine caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [151]
Ibrutinib DMHZCPO Major Decreased metabolism of Delavirdine caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [84]
Ponatinib DMYGJQO Major Decreased metabolism of Delavirdine caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [84]
Arry-162 DM1P6FR Moderate Decreased clearance of Delavirdine due to the transporter inhibition by Arry-162. Melanoma [2C30] [84]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Delavirdine caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [152]
Selumetinib DMC7W6R Major Decreased metabolism of Delavirdine caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [153]
LGX818 DMNQXV8 Major Decreased metabolism of Delavirdine caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [154]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Delavirdine caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [84]
Ethinyl estradiol DMODJ40 Minor Decreased metabolism of Delavirdine caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [71]
Ubrogepant DM749I3 Major Decreased metabolism of Delavirdine caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [155]
Almogran DM7I64Z Moderate Decreased metabolism of Delavirdine caused by Almogran mediated inhibition of CYP450 enzyme. Migraine [8A80] [156]
Rimegepant DMHOAUG Moderate Decreased metabolism of Delavirdine caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [157]
Exjade DMHPRWG Moderate Increased metabolism of Delavirdine caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [87]
Siponimod DM2R86O Major Decreased metabolism of Delavirdine caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [84]
Deflazacort DMV0RNS Major Decreased metabolism of Delavirdine caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [88]
Romidepsin DMT5GNL Moderate Decreased metabolism of Delavirdine caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [158]
Fedratinib DM4ZBK6 Major Decreased metabolism of Delavirdine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [88]
Nilotinib DM7HXWT Major Decreased metabolism of Delavirdine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [84]
Ruxolitinib DM7Q98D Major Decreased metabolism of Delavirdine caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [159]
Dasatinib DMJV2EK Major Decreased metabolism of Delavirdine caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [84]
Vorapaxar DMA16BR Major Decreased metabolism of Delavirdine caused by Vorapaxar mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [84]
Dextroamphetamine DMMIHVP Moderate Decreased metabolism of Delavirdine caused by Dextroamphetamine mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [71]
Modafinil DMYILBE Moderate Increased metabolism of Delavirdine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [160]
Netupitant DMEKAYI Minor Decreased metabolism of Delavirdine caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [161]
Entrectinib DMMPTLH Major Decreased metabolism of Delavirdine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [88]
Benzphetamine DMIJATC Moderate Decreased metabolism of Delavirdine caused by Benzphetamine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [71]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Delavirdine caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [162]
S-297995 DM26IH8 Moderate Decreased metabolism of Delavirdine caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [88]
Olaparib DM8QB1D Major Decreased metabolism of Delavirdine caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [84]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Delavirdine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [163]
Methamphetamine DMPM4SK Moderate Decreased metabolism of Delavirdine caused by Methamphetamine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [164]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Delavirdine caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [165]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Delavirdine caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [166]
Pimavanserin DMR7IVC Major Decreased metabolism of Delavirdine caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [167]
Bromocriptine DMVE3TK Minor Decreased metabolism of Delavirdine caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [101]
Abametapir DM2RX0I Moderate Decreased metabolism of Delavirdine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [168]
Ranitidine DM0GUSX Moderate Decreased absorption of Delavirdine due to altered gastric pH caused by Ranitidine. Peptic ulcer [DA61] [71]
Esomeprazole DM7BN0X Moderate Decreased absorption of Delavirdine due to altered gastric pH caused by Esomeprazole. Peptic ulcer [DA61] [71]
Famotidine DMRL3AB Moderate Decreased absorption of Delavirdine due to altered gastric pH caused by Famotidine. Peptic ulcer [DA61] [71]
Lefamulin DME6G97 Major Decreased metabolism of Delavirdine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [169]
Hydrocortisone DMGEMB7 Moderate Decreased metabolism of Delavirdine caused by Hydrocortisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [170]
Ergonovine DM0VEC1 Major Decreased metabolism of Delavirdine caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [171]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Delavirdine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [172]
ABIRATERONE DM8V75C Minor Decreased metabolism of Delavirdine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [173]
Enzalutamide DMGL19D Major Increased metabolism of Delavirdine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [80]
Darolutamide DMV7YFT Minor Decreased metabolism of Delavirdine caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [174]
Tamsulosin DM5QF9V Major Decreased metabolism of Delavirdine caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [84]
Silodosin DMJSBT6 Major Decreased metabolism of Delavirdine caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [84]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Delavirdine caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [175]
Ambrisentan DMD1QXW Minor Decreased metabolism of Delavirdine caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [176]
Riociguat DMXBLMP Moderate Decreased metabolism of Delavirdine caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [84]
Everolimus DM8X2EH Major Decreased metabolism of Delavirdine caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [84]
Axitinib DMGVH6N Major Decreased metabolism of Delavirdine caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [84]
Temsirolimus DMS104F Major Increased metabolism of Delavirdine caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [84]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Delavirdine caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [170]
Upadacitinib DM32B5U Major Decreased metabolism of Delavirdine caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [177]
Tofacitinib DMBS370 Major Decreased metabolism of Delavirdine caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [84]
Dexamethasone DMMWZET Moderate Increased metabolism of Delavirdine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [87]
Quetiapine DM1N62C Major Decreased metabolism of Delavirdine caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [178]
Iloperidone DM6AUFY Major Decreased metabolism of Delavirdine caused by Iloperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [179]
Pimozide DMW83TP Major Decreased metabolism of Delavirdine caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [84]
Sufentanil DMU7YEL Moderate Decreased metabolism of Delavirdine caused by Sufentanil mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [180]
Avanafil DM75CXN Major Decreased metabolism of Delavirdine caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [84]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Delavirdine caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [84]
Vardenafil DMTBGW8 Moderate Decreased metabolism of Delavirdine caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [181]
Voxelotor DMCS6M5 Major Decreased metabolism of Delavirdine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [182]
LDE225 DMM9F25 Major Decreased metabolism of Delavirdine caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [183]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Delavirdine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [88]
Larotrectinib DM26CQR Major Decreased metabolism of Delavirdine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [84]
Methylprednisolone DM4BDON Major Decreased metabolism of Delavirdine caused by Methylprednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [170]
Docetaxel DMDI269 Major Decreased metabolism of Delavirdine caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [184]
Trabectedin DMG3Y89 Major Decreased metabolism of Delavirdine caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [84]
Armodafinil DMGB035 Moderate Increased metabolism of Delavirdine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [160]
LEE011 DMMX75K Major Decreased metabolism of Delavirdine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [88]
Etoposide DMNH3PG Minor Decreased metabolism of Delavirdine caused by Etoposide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [101]
Prednisolone DMQ8FR2 Moderate Decreased metabolism of Delavirdine caused by Prednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [170]
Norethindrone DMTY169 Minor Decreased metabolism of Delavirdine caused by Norethindrone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [91]
Taxol DMUOT9V Major Decreased metabolism of Delavirdine caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [185]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Delavirdine caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [88]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Delavirdine caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [84]
Fostamatinib DM6AUHV Major Decreased metabolism of Delavirdine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [186]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Delavirdine due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [163]
As-1670542 DMV05SW Moderate Decreased metabolism of Delavirdine caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [88]
Apixaban DM89JLN Moderate Decreased metabolism of Delavirdine caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [88]
Brilinta DMBR01X Major Decreased metabolism of Delavirdine caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [84]
Cabozantinib DMIYDT4 Major Decreased metabolism of Delavirdine caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [84]
Sirolimus DMGW1ID Major Decreased metabolism of Delavirdine caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [84]
Tacrolimus DMZ7XNQ Major Decreased metabolism of Delavirdine caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [187]
Saxagliptin DMGXENV Moderate Decreased metabolism of Delavirdine caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [88]
Elagolix DMB2C0E Major Decreased metabolism of Delavirdine caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [188]
Fluticasone DMGCSVF Major Decreased metabolism of Delavirdine caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [189]
Flecainide DMSQDLE Moderate Decreased metabolism of Delavirdine caused by Flecainide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [71]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Delavirdine caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [71]
⏷ Show the Full List of 235 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Delavirdine 100 mg tablet 100 mg Oral Tablet Oral
Delavirdine 200 mg tablet 200 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Approved antiretroviral drugs. Antiretroviral Drugs. Company report of AVERT. 2009.
2 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9 The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109.
10 Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2001;40(3):207-26.
11 Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
12 Drug Interactions Flockhart Table
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
23 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
24 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
25 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
26 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
27 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
28 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
29 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
30 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
31 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
32 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
33 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
34 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
35 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
36 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
37 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
38 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
39 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
40 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
41 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
42 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
43 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
44 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
45 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
46 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
47 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
48 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
49 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
50 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
51 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
52 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
53 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
54 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
55 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
56 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
57 Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
58 HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
59 A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
60 Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
61 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
62 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
63 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
64 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
65 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
66 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
67 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
68 Product Information. Invirase (saquinavir). Roche Laboratories, Nutley, NJ.
69 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
70 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
71 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
72 Product Information. Cleocin (clindamycin). Pharmacia and Upjohn, Kalamazoo, MI.
73 Adamson PC "Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia." Semin Hematol 31 (1994): 14-7. [PMID: 7831580]
74 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
75 Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
76 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
77 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
78 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
79 Multum Information Services, Inc. Expert Review Panel.
80 Borin MT, Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA "Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients." Antiviral Res 35 (1997): 53-63. [PMID: 9224961]
81 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
82 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
83 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
84 Cerner Multum, Inc. "Australian Product Information.".
85 Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90. [PMID: 6882885]
86 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
87 Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW "Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate." Clin Pharmacol Ther 61 (1997): 544-53. [PMID: 9164416]
88 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
89 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
90 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
91 Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL "Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test." Clin Pharmacol Ther 61 (1997): 531-43. [PMID: 9164415]
92 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
93 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
94 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
95 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
96 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
97 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
98 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
99 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
100 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
101 Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
102 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
103 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
104 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
105 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
106 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
107 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
108 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
109 Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
110 Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]
111 Canadian Pharmacists Association.
112 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
113 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
114 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
115 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
116 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
117 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
118 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
119 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
120 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
121 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
122 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
123 Product Information. Cerebyx (fosphenytoin). Parke-Davis, Morris Plains, NJ.
124 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
125 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
126 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
127 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
128 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
129 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
130 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
131 Product Information. Lescol (fluvastatin). Novartis Pharmaceuticals, East Hanover, NJ.
132 Product Information. Sensipar (cinacalcet). Amgen USA, Thousand Oaks, CA.
133 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
134 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
135 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
136 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
137 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
138 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
139 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
140 Product Information. Pemazyre (pemigatinib). Incyte Corporation, Wilmington, DE.
141 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
142 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
143 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
144 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
145 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
146 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
147 Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C "Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine." Clin Pharmacol Ther 72 (2002): 514-23. [PMID: 12426515]
148 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
149 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
150 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
151 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
152 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
153 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
154 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
155 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
156 Product Information. Axert (almotriptan) Pharmacia and Upjohn, Kalamazoo, MI.
157 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
158 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
159 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
160 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
161 Product Information. Akynzeo (netupitant-palonosetron). Eisai Inc, Woodcliff Lake, NJ.
162 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
163 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
164 Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
165 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
166 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
167 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
168 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
169 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
170 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
171 Product Information. Cafergot (caffeine-ergotamine). Novartis Pharmaceuticals, East Hanover, NJ.
172 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
173 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
174 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
175 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
176 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
177 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
178 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
179 Product Information. Fanapt (iloperidone). Vanda Pharmaceuticals Inc, Rockville, MD.
180 Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5. [PMID: 8439020]
181 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
182 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
183 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
184 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
185 Bundow D, Aboulafia DM "Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma." Am J Clin Oncol 27 (2004): 81-4. [PMID: 14758138]
186 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
187 Albengres E, Le Louet H, Tillement JP "Systemic antifungal agents. Drug interactions of clinical significance." Drug Saf 18 (1998): 83-97. [PMID: 9512916]
188 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
189 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]